Société Générale — M&A Activity 2021

Jun 8, 2021

National Storage Mechanism | Additional information

RNS Number : 1409B

Societe Generale SA

08 June 2021

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1)	Société Générale S.A.
Company dealt in	UDG Healthcare plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	€0.05 ordinary shares
Date of dealing	07/06/2021

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
Number	(%)	Number	(%)
(1) Relevant securities	4,049,411	1.61	5,814	0.00
(2) Derivatives (other than options)	0	0.00	0	0.00
(3) Options and agreements to purchase/sell	0	0.00	0	0.00
Total	*4,109,411	*1.63	5,814	0.00

* Include the holding of 60,000 shares on borrow products

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit GBP (Note 5)
Purchase	12	10.62
Purchase	149	10.64
Purchase	54	10.64
Purchase	370	10.61
Purchase	570	10.61
Purchase	237	10.64
Purchase	250	10.64
Purchase	527	10.64
Purchase	364	10.63
Purchase	200	10.63
Purchase	2	10.64
Purchase	13	10.62
Purchase	167	10.63
Purchase	65	10.62
Purchase	66	10.63
Purchase	100	10.63
Purchase	70	10.62
Purchase	186	10.63
Purchase	34	10.62
Purchase	290	10.63
Purchase	20	10.63
Purchase	76	10.63
Purchase	241	10.62
Purchase	65	10.62
Purchase	265	10.64
Purchase	115	10.64
Purchase	200	10.64
Purchase	73	10.62
Purchase	62	10.62
Purchase	31	10.63
Purchase	14	10.62
Purchase	16	10.64
Purchase	29	10.63
Purchase	40	10.63
Purchase	290	10.63
Purchase	65	10.62
Purchase	374	10.64
Purchase	44	10.63
Purchase	44	10.63
Sale	2,090	10.6
Sale	1,216	10.6
Sale	44	10.63
Sale	65	10.62
Sale	374	10.64
Sale	44	10.63
Total Purchases	5,790
Total Sales	3,833

Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit GBP (Note 5)

(b)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(c)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements, or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any 

relevant securities to which any derivative referred to on this form is referenced. If none, this

should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            No

Date of disclosure	08/06/2021
Contact name	Société Générale - Disclosure team
Telephone number	+33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEUPUMGQUPGUQR